In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Creating J&J's Cardiology Franchise: An Interview with Marv Woodall

Executive Summary

In this interview, Marv Woodall, the architect of Johnson & Johnson's cardiology business, reflects on the ups and downs of building a stent business, integrating a hostile takeover, and why--despite all their success--stents have not met their original goal.

You may also be interested in...



Prescient Medical's Dual Approach to Vulnerable Plaque

Vulnerable plaque caught investors' and entrepreneurs' attention several years ago as the mysterious cause of more than half of all cases of sudden cardiac death, most of which occurs in people with no history of heart disease. Several companies were launched and much money invested with little to show for it. One major problem: vulnerable plaque requires new tools both to diagnose and treat the condition, which proved to be bigger hurdles than most start-ups can overcome. Prescient was launched by an experienced device management team and is applying Raman spectroscopy, to coronary disease as the basis of its diagnostic tool, and is using a shield-not a stent-for its therapeutic device.

Zydus To Slice Into Shrinking Revlimid Pie ‘In Near Term’ As Asacol Revenues Erode

Zydus is set to join Natco in chipping away at BMS’ blockbuster Revlimid with its generic version, probably from Q2 while Aurobindo expects to launch by FY24. Revenues from this drug are expected to offset erosion of gAsacol revenues even as Zydus expects volume growth and new launches to help grow its US business

GGB Awards Extend Entry Deadline To 26 August

Entrants now have an additional week to submit entries for the Global Generics & Biosimilars Awards 2022, which returns to Frankfurt this November.

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

IV003199

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel